Clinical requirements for closed-loop control systems

Journal of Diabetes Science and Technology

Volumn 6, Issue 2, 2012, Pages 444-452

  Clarke, William L ^a   Renard, Eric ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIV MONTPELLIER   (France)

Author keywords

Closed loop control; Diabetes quality of life; Diabetic ketoacidosis; Efficacy; Fear of hypoglycemia; Glucose monitoring; Glycemic variability; Glycosylated hemoglobin; Hypoglycemia; Insulin delivery; Management of insulin infusion; Noninferiority; Safety; Superiority

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

CLINICAL EFFECTIVENESS; CLOSED LOOP CONTROL SYSTEM; CONTROL SYSTEM; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFUSION SYSTEM; NOTE; PATIENT CARE; PATIENT SAFETY; QUALITY OF LIFE; TREATMENT OUTCOME; ALARM MONITOR; AUTOMATION; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EQUIPMENT DESIGN; INSTRUMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; METABOLISM; MONITORING; PREDICTIVE VALUE; REVIEW; TRANSDUCER;

AUTOMATION; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CLINICAL ALARMS; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; EQUIPMENT DESIGN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MONITORING, PHYSIOLOGIC; PREDICTIVE VALUE OF TESTS; TRANSDUCERS; TREATMENT OUTCOME;

EID: 84865152182     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600233     Document Type: Note

References (47)

1. Santiago JV, Clemens AH, Clarke WL, Kipnis DM. Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes. 1979;28(1):71-84. (Pubitemid 9103179)
2. Clarke WL, Anderson S, Kovatchev B. Evaluating clinical accuracy of continuous glucose monitoring systems: continuous glucose - error grid analysis (CG-EGA). Curr Diabetes Rev. 2008;4(3):193-9.
3. Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, Caswell K, Wilkinson J, Cameron F, Lee H, Bequette BW, Doyle FJ 3rd. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33(5):1013-17.
4. Buckingham B, Cobry E, Clinton P, Gage V, Caswell K, Kunselman E, Cameron F, Chase HP. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diab Technol Thera. 2009;11(2):93-7.
5. Elleri D, Allen JM, Nodale M, Wilinska ME, Acerini CL, Dunger DB, Hovorka R. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diab Med. 2010;27(4):480-4.
6. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-7.
7. Clarke WL, Anderson S, Breton M, Patek S, Kashmer L, Kovatchev B. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 2009;3(5):1031-8.
8. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-51.
9. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11):2672-82.
10. The Diabetes Control and Complications Trial Research Group. The efect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
11. De Beaufort C, Swift P, Skinner CT, Aanstoot HJ, Aman J, Cameron F, Martul P, Chiarelli F, Daneman D, Danne T, Dorchy H, Hoey H, Kaprio EA, Kaufman F, Kocova M, Mortensen HB, Njølstad PR, Phillip M, Robertson KJ, Schoenle EJ, Urakami T, Vanelli M; Hvidoere Study Group on Childhood Diabetes 2005. Continuing stability of center diferences in pediatric diabetes care: do advances in diabetes treatment improve outcome? Diabetes Care. 2007;30(9):2245-50. (Pubitemid 47359026)
12. Petitti DB, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder B, Mayer-Davis E. Glycemic control in youth with diabetes: the SEARCH for diabetes in youth study. J Pediatr. 2009;155(5):668-72.
13. Fritsch M, Rosenbauer J, Schober E, Neu A, Placzek K, Holl RW; German Competence Network Diabetes Mellitus and the DPV Initiative. Predictors of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Experience from a large multicentre database. Pediatr Diabetes. 2011;12(4 Pt 1):307-12.
14. Cengiz E, Wolfsdorf J, Miller KM for the TID Exchange Clinic Network. Resetting the bar: frequency of severe hypoglycmeia (SH) and diabetic ketoacidosis (DKA) among children with type 1 diabetes (TID) in the TID exchange registry cohort. Pediatr Diabetes. 2011;12 Suppl 15:53-4.
15. Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M, Hamman RF, Klingensmith G. Predictors of acute complications in children with type 1 diabetes. JAMA. 2002;287(19):2511-18. (Pubitemid 34517196)
16. UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes; effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-7.
17. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant T, Band MM, Reekie G, Leese GP; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749-55. (Pubitemid 40805897)
18. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern day clinical course of type 1 diabetes mellitus after 30 years' duration. Arch Intern Med. 2009;169(14):1307-16.
19. Fiallo-Scharer R, Cheng J, Beck RW, Buckingham BA, Chase HP, Kollman C, Laffel L, Lawrence JM, Mauras N, Tamborlane WV, Wilson DM, Wolpert H; The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. Diabetes Care. 2011;34(3):586-90.
20. O'Connell SM, Cooper MN, Bulsara MK, Davis EA, Jones TW. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000-2009. Diabetes Care. 2011;34(11):2379-80.
21. Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ, Pitukcheewanont P. Nocturnal hypoglycemia detected with the continuous glucose monitoring system in pediatric patients with type 1 diabetes. J Pediatr. 2002;141(5):625-30. (Pubitemid 35292759)
22. Wolpert HA. Use of continuous glucose monitoring in the detection and prevention of hypoglycemia. J Diabetes Sci Technol. 2007;1(1):146-50.
23. Amin R, Ross K, Acerini CL, Edge JA, Warner J, Dunger DB. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care. 2003;26(3):662-7. (Pubitemid 36929324)
24. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemia excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44-50. (Pubitemid 44033429)
25. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care. 2010;33(5):1004-8.
26. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Lafel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D; The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-76.
27. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Efectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-20.
28. Beck RW, Kollman C, Xing D, Buckingham BA, Chase HP. Outcome measures for outpatient prevention studies. J Diabetes Sci Technol. 2011;5(4):999-1004.
29. Karges B, Kapellen T, Neu A, Hofer SE, Rohrer T, Rosenbauer J, Wolf J, Holl RW; Diabetes Prospective Documentation DPV Initiative; German Federal Ministry for Education and Research BMBF Competence Network of Diabetes Mellitus. Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Diabetes Care. 2010;33(5):1031-3.
30. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes. 2009;16(2):113-18.
31. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-8.
32. Diabetes Control and Complications Trial Research Group. Efect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125(2):177-88.
33. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care. 2010;33 Suppl 1:S11-67.
34. Brownlee M, Hirsch IB. Glycemia variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295(14):1707-8.
35. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008;2(6):1094-100.
36. Hirsch IB, Brownlee M. Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA. 2010;303(22):2291-2.
37. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes; normative values. Diabetes Care. 2005;28(10):2361-6. (Pubitemid 41384277)
38. Clarke W, Kovatchev B. Statistical tools to analyze continuous glucose monitor data. Diab Technol Thera. 2009;11 Suppl 1:S45-54.
39. Diabetes Research in Children Network (DirecNet) Study Group. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007;151(4):388-93.
40. Magni L, Raimondo FM, Man CD, Breton M, Patek S, DeNicolao G, Cobelli C, Kovatchev BP. Evaluating the eficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol. 2009;2(4):630-5.
41. The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 1988;11(9):725-32.
42. Beck RW, Lawrence JM, Lafel L, Wysocki T, Xing D, Huang ES, Ives B, Kollman C, Lee J, Ruedy KJ, Tamborlane WV; The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care. 2010;33(12):2175-7.
43. Wild D, von Maltzah R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68(1):10-15. (Pubitemid 47126791)
44. Renard E, Guerci B, Leguerrier AM, Boizel R; Accu-Chek FlexLink Study Group. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther. 2010;12(10): 769-73.
45. Clausen TS, Kaastrup P, Stallknecht B. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther. 2009;11(9):575-80.
46. Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31(6):1160-4.
47. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Draft Guidance for Industry and Food and Drug Administration Staf: The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. Document Number 1786, December 2011:1-60.